| » |
Xcovery's kinase technology and know-how has been demonstrated
to discover and develop validated inhibitor leads with superior drug
properties quicker, and with lower risk than comparable efforts. |
| |
|
| » |
Xcovery can discover and develop preclinical lead
candidates with properties superior to existing lead compounds
in less than 18 months. |
| » |
The Xcovery approach (VIRDD*) produces inhibitors
with greatly reduced toxicity, as Xcovery inhibitors target only
the diseased
cells. |
|
|
| » |
Xcovery will team the best kinase medicinal chemistry with the best
of early stage biotech mamanement and value creation to develop targeted,
less toxic therapies with biopharma partners and as proprietary efforts. |
|
| |
| *VIRDD : Vertically Integrated Rational Drug Design |
| |
|